CN Patent

CN101384251B — 含胰岛素敏化剂的固体制剂

Assigned to Takeda Pharmaceutical Co Ltd · Expires 2014-09-03 · 12y expired

What this patent protects

本发明提供了固体制剂，其包含胰岛素敏化剂和除胰岛素敏化剂外的活性组分，并且显示出胰岛素敏化剂的溶出特性与从“仅仅包含胰岛素敏化剂作为活性组分的固体制剂”的胰岛素敏化剂的溶出特性相似。该固体制剂包括：“含有包衣颗粒的部分，其中该包衣颗粒含有胰岛素敏化剂并且用乳糖或糖醇包衣”，和“含有除胰岛素敏化剂外的活性组分的部分”。

USPTO Abstract

本发明提供了固体制剂，其包含胰岛素敏化剂和除胰岛素敏化剂外的活性组分，并且显示出胰岛素敏化剂的溶出特性与从“仅仅包含胰岛素敏化剂作为活性组分的固体制剂”的胰岛素敏化剂的溶出特性相似。该固体制剂包括：“含有包衣颗粒的部分，其中该包衣颗粒含有胰岛素敏化剂并且用乳糖或糖醇包衣”，和“含有除胰岛素敏化剂外的活性组分的部分”。

Drugs covered by this patent

Amaryl (GLIMEPIRIDE) · Sanofi

Patent Metadata

Patent number: CN101384251B
Jurisdiction: CN
Classification: —
Expires: 2014-09-03
Drug substance claim: No
Drug product claim: No
Assignee: Takeda Pharmaceutical Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.